Remove Diet Remove Obesity Remove Public Health
article thumbnail

Ultraprocessed Foods & Cardiometabolic Disease

Physiologically Speaking

The consumption of ultraprocessed foods is increasing worldwide, and damning evidence implicates these “foods” in the diseases of civilization — type 2 diabetes, obesity, and cardiovascular disease. There’s no denying it — diet quality worldwide has declined dramatically in the last few decades. .”

Diet 98
article thumbnail

Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050—Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association

Circulation

to 26.8%) and obesity (43.1% The prevalences of poor diet, inadequate physical activity, and smoking are estimated to improve over time, whereas inadequate sleep will worsen. Clinical and public health interventions are needed to effectively manage, stem, and even reverse these adverse trends. in 2020 to 61.0%

article thumbnail

National AFib Awareness Month: A Call to Action for Physicians Worldwide

ADN Center of Excellence

The Growing Global Burden of AFib The global incidence of AFib is on the rise, making it a significant public health concern. Factors such as aging populations, rising rates of obesity, hypertension, and other cardiovascular conditions contribute to this increase.

AFIB 59
article thumbnail

National Hispanic Heritage Month 2023 Faculty Spotlight: Dr. Fatima Rodriguez

Cardiometabolic Health Congress

Cardiometabolic Health Congress faculty member, Fátima Rodriguez, MD, MPH, has committed much of her clinical and research efforts to reducing health disparities in Hispanic-American communities. Cardiometabolic conditions – specifically obesity, diabetes and heart disease – disproportionately affect the 60 million people in the U.S.

article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

Food and Drug Administration ( FDA ) has approved an additional indication for Wegovy ( semaglutide ) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.

Obesity 111